Browse Trials
Find Breast Cancer Clinical Trials That Are Right For You
The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.
Use the search box and filters to find a trial that’s right for you.
Currently viewing trials
(Last updated: July 04, 2025)
Brain Mets
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Leptomeningeal Disease
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: ADC
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Activities
Complementary and Integrative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Healthy/High Risk
Imaging
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Support/Education
Surveys/Interviews/Registries
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
dMMR/MSI-H
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT05377996
XMT-1660 Antibody Drug Conjugate for Advanced Breast Cancer
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-1660, by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-1660 is an experimental antibody-drug <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">XMT-1660's <span class="highlight">antibody</span> targets B7-H4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called dolasynthen.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05377996' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 3 miles
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies
San Francisco,CA
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT06157892
Disitamab Vedotin Antibody Drug Conjugate for Advanced HER2 Low or HER2+ Breast Cancer
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Disitamab vedotin</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Disitamab vedotin</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Disitamab vedotin is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in disitamab vedotin targets HER2 proteins. It delivers the chemotherapy MMAE.</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06157892' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.seagen.com/science/technologies' target='_blank'>Pfizer: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.seagen.com/science/technologies' target='_blank'>Seagen: ADC Information Page</a> </li></ul>
NEAREST SITE: 3 miles
Ucsf /Id# 257705
San Francisco,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06084481
ABBV-400 ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-400, by IV</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-400 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">ABBV-400's <span class="highlight">antibody</span> targets cMet, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06084481' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abbvie.com/science/pipeline.html' target='_blank'>AbbVie: ABBV-400 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 27 miles
Stanford University Medical Center
Stanford,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT05514717
XMT-2056 ADC for Advanced HER2+ or HER2 Mutated Breast Cancer
A Phase 1, First in Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2 Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-2056, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XMT-2056 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">XMT-2056's <span class="highlight">antibody</span> targets HER2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called Immunosynthen.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: HER2</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05514717' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mersana.com/pipeline/overview/' target='_blank'>Mersana Therapeutics Drug Information Page: XMT-2056</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mersana.com/our-technology-platforms/about-adcs/' target='_blank'>Mersana Therapeutics: About ADCs</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mersana.com/our-technology-platforms/immunosynthen/' target='_blank'>Mersana Therapeutics: Immunosynthen</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 27 miles
Stanford University School of Medicine
Stanford,CA
VISITS: 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT04300556
Experimental Antibody-Drug Conjugate MORAb-202 for Women with Metastatic Triple Negative Breast Cancer that Tests Positive for FRA
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MORAb-202, by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells. Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">MORAb-202 is an experimental ADC. </li> <li class="seamTextUnorderedListItem">Its <span class="highlight">antibody</span> targets FAR, a protein, and it delivers an anti-cancer <span class="highlight">drug</span> called eribulin mesylate.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling women with other types of cancer. </li> <li class="seamTextUnorderedListItem">Targets or mutations: FRA</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04300556' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Getting to the Target, Antibody-Drug Conjugates</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.5544' target='_blank'>Journal Article Abstract: MORAb-202</a> </li></ul>
NEAREST SITE: 53 miles
Providence Medical Foundation
Santa Rosa,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT05579366
PRO1184 Antibody Drug Conjugate for Advanced HER2- Breast Cancer that Expresses FRA
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRO1184, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRO1184 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">BB-1701's <span class="highlight">antibody</span> targets folate receptor alpha (FRA), a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called exatecan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: FRA</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05579366' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prnewswire.com/news-releases/profoundbio-receives-fda-study-may-proceed-letter-for-pro1184-a-folate-receptor-alpha-directed-adc-with-a-topoisomerase-1-inhibitor-payload-and-welcomes-naomi-hunder-md-as-chief-medical-officer-301598943.html?tc=em' target='_blank'>ProfoundBio Press Release: PRO1184</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 53 miles
Research Site
Santa Rosa,CA
VISITS: Number of visits unavailable
PHASE: III
NCT ID: NCT06103864
Dato-DXd ADC With or Without Durvalumab Immunotherapy for Advanced Triple Negative, PD-L1 Positive Breast Cancer
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast (TROPION-Breast05) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV</li> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd) is an experimental antibody-drug <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan's <span class="highlight">antibody</span> targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®) and pembrolizumab (Keytruda®) are a type of immunotherapy called PD-1 inhibitors, which are a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">In this trial, standard of care chemotherapy drugs include carboplatin (Paraplatin®), paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), and/or gemcitabine (Gemzar®).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06103864' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astrazenecaclinicaltrials.com/study/D7630C00001/' target='_blank'>AstraZeneca: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/october-10-2022-supplement-breast-cancer-almanac/datopotamab-deruxtecan-shows-activity-in-advanced-triple-negative-breast-cancer/' target='_blank'>ASCO: Datopotamab Deruxtecan (Dato-DXd)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertherapyadvisor.com/home/news/conference-coverage/asco-2021/asco-2021-breast-cancer-in-depth/breast-cancer-durvalumab-neoadjuvant-chemo-treatment-risk/#:~:text=June%2024%2C%202021-,Durvalumab%20Improves%20Survival%20When%20Added%20to,in%2' target='_blank'>Cancer Therapy Advisor: Durvalumab (Imfinzi®)</a> </li></ul>
NEAREST SITE: 74 miles
University of California Davis Comprehensive Cancer Center
Sacramento,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT05208762
SGN-PDL1V Antibody Drug Conjugate for Advanced Triple Negative Breast Cancer
A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-PDL1V, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-PDL1V is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Its <span class="highlight">antibody</span> targets PD-1/PD-L1, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called vedotin.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05208762' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.clinicaltrials.seagen.com/study/?pid=SGNPDL1V-001' target='_blank'>Seagen Trial Information Page: SGN-PDL1V</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://investor.seagen.com/press-releases/news-details/2021/Seagen-to-Highlight-Two-Novel-Antibody-Drug-Conjugates-ADCs-at-the-SITC-36th-Annual-Meeting/default.aspx' target='_blank'>Seagen Press Release: SGN-PDL1V</a> </li></ul>
NEAREST SITE: 74 miles
University of California, Davis Comprehensive Cancer Center
Sacramento,CA
VISITS: 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT05785741
DB-1310 Antibody Drug Conjugate for Advanced Breast Cancer
A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1310, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1310 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">DB-1310's <span class="highlight">antibody</span> targets HER3, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05785741' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dualitybiologics.com/approach.html?md=1' target='_blank'>DualityBio: ADC Information Page</a> </li></ul>
NEAREST SITE: 75 miles
Research Site 1143-0
Sacramento,CA
VISITS: 1 visit every 1-3 weeks
PHASE: III
NCT ID: NCT06018337
DB-1303/BNT323 Antibody Drug Conjugate for Advanced HR+, HER2 Low Breast Cancer
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1303/BNT323, by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care Chemotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One of the following:</li> <li class="seamTextUnorderedListItem">Capecitabine (Cytoxan®), by mouth, daily, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, weekly, 3 weeks on, 1 week off</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DB-1303/BNT323 is an experimental antibody-drug <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">DB-1303/BNT323's <span class="highlight">antibody</span> targets HER2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">Capecitabine (Cytoxan®), paclitaxel (Taxol®), or nab-paclitaxel (Abraxane®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06018337' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dualitybiologics.com/pipeline.html' target='_blank'>DualityBio: DB-1303 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dualitybiologics.com/approach.html?md=1' target='_blank'>DualityBio: ADC Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 186 miles
Renown Regional Medical Center ( Site 0005)
Reno,NV
VISITS: At least 1 visit every 1-4 weeks
PHASE: III
NCT ID: NCT06841354
Sacituzumab Tirumotecan ADC With and Without Immunotherapy for Advanced Triple Negative Breast Cancer
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing..(MK-2870-011) (TroFuse-011) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (Sac-TMT, MK-2870), by IV, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (Sac-TMT, MK-2870), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 1.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy, by IV, every 1-4 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan's <span class="highlight">antibody</span> targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06841354' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/july-10-2024/novel-antibody-drug-conjugate-extends-survival-vs-chemotherapy-in-triple-negative-breast-cancer/' target='_blank'>ASCO: Sacituzumab Tirumotecan ADC Extends Survival vs. Chemotherapy in Triple Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 336 miles
UCLA Medical Center
Los Angeles,CA
VISITS: 1 visit every 3 weeks for 9 months, then every 1.5 months
PHASE: I-II
NCT ID: NCT06247995
Radioactive Drug with Chemotherapy for Metastatic ER+, HER2- or HER2 Low, GRPR+ Breast Cancer
A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inh...(NeoB-Cap1) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">177Lu-Lu-NeoB, by IV, every 3-6 weeks</li> <li class="seamTextUnorderedListItem">Capecitabine (Cytoxan®), by mouth, daily, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">PET/CT or PET/MRI scan with 68Ga-Ga-NeoB, by IV, 1-2 times</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are developing a new class of drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells.</li> <li class="seamTextUnorderedListItem">177Lu-Lu-NeoB is an experimental radiation therapy <span class="highlight">drug</span> called a radiopharmaceutical or radioactive drug.</li> <li class="seamTextUnorderedListItem">177Lu-Lu-NeoB targets tumors that are positive for GRPR (gastrin releasing peptide receptor).</li> <li class="seamTextUnorderedListItem">Capecitabine (Cytoxan®) is an FDA-approved chemotherapy drug.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The experimental tracer in this study is 68Ga-Ga-NeoB.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06247995' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.novartis.com/clinicaltrials/study/NCT06247995' target='_blank'>Novartis: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/services-and-locations/radiopharmaceuticals/#:~:text=Radiopharmaceuticals%20are%20a%20unique%20class,linker%20that%20joins%20the%20two.' target='_blank'>Moffitt Cancer Center: Radiopharmaceuticals</a> </li></ul>
NEAREST SITE: 336 miles
UCLA Department of Medicine-Hematology/Oncology
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT04389632
SGN-B6A in Advanced Breast Cancer
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-B6A, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-B6A is an investigational therapy. This means it is only available in a clinical trial.</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a cancer therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a <span class="highlight">drug</span> that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">SGN-B6A is an antibody-drug <span class="highlight">conjugate</span> (ADC) targeting integrin beta-6. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced or <span class="highlight">metastatic</span> cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04389632' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org' target='_blank'>Metastatic Breast Cancer Network</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biospace.com/article/releases/seattle-genetics-announces-initiation-of-phase-1-clinical-trials-for-two-novel-antibody-based-drug-candidates/' target='_blank'>BioSpace Press Release: Seagen Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates</a> </li></ul>
NEAREST SITE: 339 miles
UCLA
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06036121
ADRX-0706 Antibody Drug Conjugate for Advanced Triple Negative Breast Cancer
A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ADRX-0706</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ADRX-0706 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">ADRX-0706's <span class="highlight">antibody</span> targets nectin-4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06036121' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 339 miles
UCLA Santa Monica
Santa Monica,CA
VISITS: 1 visit every 1-2 weeks
PHASE: I
NCT ID: NCT05983432
BL-B01D1 ADC for Advanced HER2- Breast Cancer
A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors (BL-B01D1-LUNG-101) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-B01D1, by IV, weekly, 2 weeks on, 1 week off</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-B01D1, by IV, weekly</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-B01D1 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in BL-B01D1 targets EGFR and HER3 proteins and delivers a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05983432' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://systimmune.com/bl-m01d1' target='_blank'>SystImmune: BL-B01D1 Drug Information Page</a> </li></ul>
NEAREST SITE: 340 miles
Valkyrie Clinical Trials
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT06324357
Zongertinib Targeted Therapy with ADC for Advanced HER2+ Breast Cancer
Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cance... Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zongertinib (BI 1810631), by mouth</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®), by IV</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zongertinib (BI 1810631), by mouth</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zongertinib is an experimental anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®) and trastuzumab emtansine (T-DM1, Kadcyla®) are <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugates</span> (ADCs).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called DM1.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06324357' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.boehringer-ingelheim.com/science/human-pharma/clinical-pipeline/oncology/zongertinib-her2-tyrosine-kinase-inhibitor-tki' target='_blank'>Boehringer Ingelheim: Zongertinib (BI 1810631) Drug Information Page</a> </li></ul>
NEAREST SITE: 340 miles
Valkyrie Clinical Trials
Los Angeles,CA
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT06244485
Valemetostat Tosylate Targeted Therapy with ADC for Advanced HER2 Low Breast Cancer
A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Valemetostat tosylate, by mouth, daily</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Valemetostat tosylate is an experimental targeted therapy called a EZH1/2 inhibitor. Blocking EZH1/2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®) is an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADCs).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06244485' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.daiichisankyo.com/rd/pipeline/' target='_blank'>Daiichi Sankyo: Valemetostat Tosylate Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li></ul>
NEAREST SITE: 340 miles
Ascendis Pharma Investigational Site
Los Angeles,CA
VISITS: At least 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT05081609
TransCon IL-2 β/γ Immunotherapy with Trastuzumab or Trastuzumab Emtansine (T-DM1) for Metastatic 3rd Line or Later HER2+ Breast Cancer
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TransCon IL-2 β/γ, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) or Trastuzumab emtansine (T-DM1, Kadcyla®), by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TransCon IL-2 β/γ is an experimental immunotherapy that includes interleukin-2 (IL-2) and may work better than IL-2 alone.</li> <li class="seamTextUnorderedListItem">IL-2 activates immune cells to kill cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy routinely used for HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®) is an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An ADC is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">T-DM1's <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called emtansine.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05081609' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascendispharma.com/pipeline/oncology/' target='_blank'>Ascendis Pharma: TransCon Drug Information Page</a> </li></ul>
NEAREST SITE: 341 miles
Cedars Sinai Medical Center
Los Angeles,CA
VISITS: 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT05941507
LCB84 Antibody Drug Conjugate With and Without Immunotherapy for Advanced Breast Cancer
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84, by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">PD-1 inhibitor, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LCB84 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">LCB84's <span class="highlight">antibody</span> targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called MMAE.</li> <li class="seamTextUnorderedListItem">PD-1 inhibitors are a type of immunotherapy called immune checkpoint inhibitors. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05941507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/immune-checkpoint-inhibitor/?utm_medium=email&utm_source=subscribers&utm_campaign=Oct2023&utm_content=Email102023' target='_blank'>Metastatic Trial Talk: Update on Immunotherapy for MBC: Immune Checkpoint Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors' target='_blank'>National Cancer Institute: Immune Checkpoint Inhibitors</a> </li></ul>
NEAREST SITE: 346 miles
Los Angeles Cancer Network (LACN) - Good Sam
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT06926920
Sacituzumab Govitecan ADC at a Different Dose and Schedule in Advanced Triple Negative Breast Cancer
A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy), by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is FDA approved for advanced triple negative breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is studying a new way to give sacituzumab govitecan (Trodelvy®).</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers a chemotherapy <span class="highlight">drug</span> to cancer cells with TROP2.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06926920' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 346 miles
Los Angeles Cancer Network
Los Angeles,CA
VISITS: 1 visit every 3 weeks
PHASE: II
NCT ID: NCT06330064
Ifinatamab Deruxtecan ADC for Advanced HER2 Low or HER2 Negative Breast Cancer
A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ifinatamab deruxtecan (I-DXd), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ifinatamab deruxtecan (I-DXd) is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Ifinatamab deruxtecan (I-DXd)'s <span class="highlight">antibody</span> targets B7-H3, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 2+/ISH- or IHC 1+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06330064' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/news/january-2024/antibody-drug-conjugate-ifinatamab-deruxtecan-shows-robust-activity-in-refractory-small-cell-lung-cancer/' target='_blank'>ASCO: Antibody-Drug Conjugate Ifinatamab Deruxtecan for Small Cell Lung Cancer</a> </li></ul>
NEAREST SITE: 353 miles
Exelixis Clinical Site #4
Duarte,CA
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT06545331
XB010 ADC for Advanced HR+ or Triple Negative Breast Cancer
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XB010, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XB010 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">XB0101's <span class="highlight">antibody</span> targets 5T4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06545331' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.exelixis.com/clinical-trials-pipeline/' target='_blank'>Exelixis: XB010 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 353 miles
City of Hope
Duarte,CA
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT06293898
BL-M07D1 ADC for Advanced HER2 Positive, HER2 Low, and HER2 Expressing Breast Cancer
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-M07D1, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BL-M07D1 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">BL-M07D1's <span class="highlight">antibody</span> targets HER2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called trastuzumab.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06293898' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://systimmune.com/bl-m07d1' target='_blank'>SystImmune: BL-M07D1 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA
VISITS: 1 visit every 1-2 months
PHASE: IV
NCT ID: NCT05376878
PET/MRI Scan to Determine Response to Treatment for People with Metastatic HER2+ Breast Cancer with Brain or Leptomeninges Metastasis
Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, 1 time</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">64Cu-DOTA-trastuzumab, by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/MRI scan, 1 time</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI scan, every 1.5 months for 6 months, then every 2 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">64Cu-DOTA-trastuzumab is an experimental tracer that detects cancer cells during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive tracer to look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy.</li> <li class="seamTextUnorderedListItem">The results of your PET/MRI scan will find the cancer in your brain and may predict your response to treatment.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is a type of anti-HER2 targeted therapy used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is an antibody-drug <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05376878' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cedars-sinai.org/programs/imaging-center/exams/nuclear-medicine/pet-mri.html' target='_blank'>Cedars-Sinai: PET/MRI Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab deruxtecan (Enhertu®)</a> </li></ul>
NEAREST SITE: 362 miles
Innovative Clinical Research Institute
Whittier,CA
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT05593094
ZN-A-1041 Targeted Therapy for Advanced HER2 Positive or HER2 Low Breast Cancer
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-A-1041, by mouth, daily</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-A-1041, by mouth, daily</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-Dxd), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-A-1041, by mouth, daily</li> <li class="seamTextUnorderedListItem">Pertuzumab/trastuzumab (PHESGO®), by injection, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-A-1041 is an experimental anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®) and trastuzumab deruxtecan (T-Dxd, Enhertu®) are <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugates</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine and trastuzumab deruxtecan target HER2 and deliver anti-cancer drugs.</li> <li class="seamTextUnorderedListItem">Pertuzumab/trastuzumab (PHESGO®) is a combination of two anti-HER2 targeted therapies, pertuzumab (Perjeta®) and trastuzumab (Herceptin®). You may also receive the two drugs separately.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05593094' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.businesswire.com/news/home/20200907005109/en/Zion-Pharma-Announces-Initiation-of-Phase-1-Study' target='_blank'>Zion Pharma Press Release: ZN-A-1041</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/kadcyla' target='_blank'>Breastcancer.org: Trastuzumab emtansine (T-DM1, Kadcyla®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab deruxtecan (T-Dxd, Enhertu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/phesgo' target='_blank'>Breastcancer.org: Pertuzumab/trastuzumab (PHESGO®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-anti-her2-therapies' target='_blank'>Breastcancer.org: Anti-HER2 Targeted Therapy</a> </li></ul>
NEAREST SITE: 366 miles
Cancer and Blood Specialty Clinic ( Site 0001)
Los Alamitos,CA
VISITS: Number of visits unavailable
PHASE: III
NCT ID: NCT06312176
Sacituzumab Tirumotecan ADC for Advanced HR+, HER2- Breast Cancer
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (MK-2870), by IV, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (MK-2870), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 1.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab tirumotecan (MK-2870) is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab tirumotecan (MK-2870) targets TROP2 proteins. It delivers the chemotherapy belotecan.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06312176' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.merck.com/research/product-pipeline/' target='_blank'>Merck: Sacituzumab Tirumotecan (MK-2870) Drug Information Page</a> </li></ul>
NEAREST SITE: 381 miles
Hoag Memorial Hospital Presbyterian
Newport,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT05455619
Evexomostat for Women with Advanced HR+, HER2- Breast Cancer with a PIK3CA Mutation and High Blood Sugar
Phase 1b/2 Study of the Safety and Efficacy of Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Advanced Breast Cancer and a PIK3CA Mutation Following Endocrine Therapy and a CDK4/6 Inhibitor Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320)</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®)</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320) is an experimental polymer <span class="highlight">drug</span> <span class="highlight">conjugate</span> (PDC), which is similar to an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320) releases fumagillol, a type of targeted therapy called a MetAP2 inhibitor. Blocking MetAP2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor downregulator (SERD). SERDs bind to and break down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women will also be given a <span class="highlight">drug</span> that will put women in temporary menopause.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05455619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.amelia1.com/' target='_blank'>SynDevRx: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://syndevrx.com/lead-compound-sdx-7320/' target='_blank'>SynDevRx Drug Information Page: Evexomostat (SDX-7320)</a> </li><li class='seamTextUnorderedListItem'><a href='https://syndevrx.com/science/polymer-drug-conjugation/' target='_blank'>SynDevRx: Polymer Drug Conjugates</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/faslodex' target='_blank'>Breastcancer.org: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li></ul>
NEAREST SITE: 441 miles
Research Site
La Jolla,CA
VISITS: 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT06956690
ENV-501 Antibody Drug Conjugate for Advanced HR+, HER2-, HER3+ Breast Cancer
A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ENV-501, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ENV-501 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in disitamab vedotin targets HER3 proteins. It delivers the chemotherapy exatecan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06956690' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://endeavorbiomedicines.com/our-science/env-501/' target='_blank'>Endeavor Biomedicines: ENV-501 Drug Information Page</a> </li></ul>
NEAREST SITE: 538 miles
Compass Oncology - Rose Quarter Cancer Center
Portland,OR
VISITS: 1 visit every 1-2 weeks
PHASE: II
NCT ID: NCT06840483
Zelenectide Pevedotin Targeted Therapy for Advanced HR+, HER2- or Triple Negative Breast Cancer That Expresses NECTIN4
Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zelenectide pevedotin (BT8009), weekly, 2 weeks on, 1 week off</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zelenectide pevedotin is an experimental targeted therapy called a bicycle <span class="highlight">drug</span> <span class="highlight">conjugate</span> (BDC), which is similar to an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">A bicycle <span class="highlight">drug</span> <span class="highlight">conjugate</span> (BDC) is a type of therapy that combines a <span class="highlight">drug</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Zelenectide pevedotin's <span class="highlight">antibody</span> targets NECTIN4, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called MMAE.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+/ISH- or IHC 2/ISH-+.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06840483' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bicycletherapeutics.com/pipeline/pipeline/' target='_blank'>Bicycle Therapeutics: Zelenectide Pevedotin Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/first-in-class-bicycle-toxin-conjugate-targeting-nectin-4-generates-excitement-in-urothelial-carcinoma' target='_blank'>OncLive: Zelenectide Pevedotin for Advanced Urinary Tract Cancer</a> </li></ul>
NEAREST SITE: 595 miles
START Mountain Region
West Valley City,UT
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06400472
LY4170156 ADC for Advanced Triple Negative Breast Cancer
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4170156, by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4170156 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in LY4170156 targets folate receptor alpha and delivers a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06400472' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://trials.lilly.com/en-US/trial/482318' target='_blank'>Eli Lilly and Company: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 601 miles
START Mountain
West Valley City,UT
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06638307
MEN2312 Targeted Therapy Alone or with Hormone Therapy for Advanced HR+ Breast Cancer
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312, by mouth</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®), by mouth</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEN2312 is an experimental targeted therapy called a KAT6 inhibitor. Blocking KAT6 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Elacestrant (Orserdu®) is a hormone therapy called a selective estrogen receptor degrader (SERD). SERDs work by binding to and breaking down estrogen receptors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06638307' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://stemline.com/product-pipeline/' target='_blank'>Stemline Therapeutics: MEN2312 Drug Information Page</a> </li></ul>
NEAREST SITE: 657 miles
HonorHealth Research Institute
Scottsdale,AZ
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT05720117
PYX-201 Antibody Drug Conjugate for Advanced Triple Negative and HR+, HER2- Breast Cancer
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PYX-201, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PYX-201 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">PYX-201's <span class="highlight">antibody</span> targets EDB fibronectin and delivers an anti-cancer <span class="highlight">drug</span> called auristatin.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05720117' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/pyx-201-generates-responses-and-contributes-to-growing-adc-use-in-solid-tumors' target='_blank'>OncLive: PYX-201 for Solid Tumors</a> </li></ul>
NEAREST SITE: 657 miles
HonorHealth Research Institute
Scottsdale,AZ
VISITS: 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT06171789
PRO1107 Antibody Drug Conjugate for Advanced Triple Negative Breast Cancer
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRO1107, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRO1107 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in PRO1107 targets PTK7 proteins. It delivers the chemotherapy auristatin.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06171789' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ
VISITS: At least 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT05824975
GI-102 Bispecific Antibody Alone or With Immunotherapy for Advanced Breast Cancer
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patient...(KEYNOTE-G08) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 5 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV or injection, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Chemotherapy, by IV, every 1-3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 5</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), by IV, every 2 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GI-102 is an experimental immunotherapy called a bispecific antibody.</li> <li class="seamTextUnorderedListItem">A bispecific <span class="highlight">antibody</span> binds to two different targets and may work better than traditional <span class="highlight">antibody</span> drugs.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd) is an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">The chemotherapies being used in this study are doxorubicin (Doxil®), paclitaxel (Taxol®), and eribulin (Halaven®).</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®) is a targeted therapy called a VEGF inhibitor. Blocking VEGF may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05824975' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/bispecific-antibodies-for-mbc/' target='_blank'>Metastatic Trial Talk: Bispecific Antibodies: An Emerging Class Of MBC Drugs</a> </li></ul>
NEAREST SITE: 733 miles
Summit Cancer Center
Spokane Valley,WA
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT05653752
YL202 ADC for Advanced HR+, HER2- Breast Cancer
A Phase 1, Multicenter, Open-label, First-in-human Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">YL202, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">YL202 is an experimental targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">YL202's <span class="highlight">antibody</span> targets proteins expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called camptothecin.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05653752' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medilinkthera.com/technology' target='_blank'>MediLink Therapeutics Drug Information Page: ADC</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 1387 miles
Stephenson Cancer Center - Oncology
Oklahoma City,OK
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT05898399
ART6043 Targeted Therapy for Advanced HER2- Breast Cancer with a BRCA Mutation
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ART6043, by mouth</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) or talazoparib (Talzenna®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) or talazoparib (Talzenna®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ART6043 is an experimental targeted therapy called a DNA polymerase theta inhibitor. DNA polymerase theta inhibitors work by blocking the action of DNA polymerase theta, an enzyme that helps cancer cells repair DNA.</li> <li class="seamTextUnorderedListItem">Olaparib (Lynpara®) and talazoparib (Talzenna®) are types of targeted therapy called PARP inhibitors. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps cancer cells repair DNA.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05898399' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.artios.com/pipeline/' target='_blank'>Artios Pharma: ART6043 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/lynparza' target='_blank'>Breastcancer.org: Olaparib (Lynparza®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/talzenna' target='_blank'>Breastcancer.org: Talazoparib (Talzenna®)</a> </li></ul>
NEAREST SITE: 1455 miles
Sanford Health Worthington
Worthington,MN
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT05889988
Studying Nerve Pain from T-DM1 in People with Stage I-IV HER2 Positive Breast Cancer
A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropathy is nerve pain in your hands and feet as a side effect of cancer treatment. Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1, Kadcyla®) is an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An ADC is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells. Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">T-DM1's <span class="highlight">antibody</span> targets HER2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called emtansine.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05889988' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/kadcyla' target='_blank'>Breastcancer.org: Trastuzumab Emtansine (T-DM1, Kadcyla®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/neuropathy' target='_blank'>Breastcancer.org: Nerve Pain</a> </li></ul>
NEAREST SITE: 1471 miles
NEXT Oncology - Dallas
Dallas,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06781983
IPH4502 Antibody Drug Conjugate for Advanced Triple Negative Breast Cancer
A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IPH4502</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IPH4502 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in IPH4502 targets Nectin-4 proteins. It delivers the chemotherapy MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06781983' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.innate-pharma.com/products/iph4502-antibody-drug-conjugate' target='_blank'>Innate Pharma: IPH4502 Drug Information Page</a> </li></ul>
NEAREST SITE: 1471 miles
NEXT Oncology - Dallas
Irving,TX
VISITS: 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT06657222
TUB-030 Antibody Drug Conjugate for Advanced Triple Negative and HR+, HER2- Breast Cancer
A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TUB-030, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TUB-030 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in TUB-030 targets 5T4 proteins. It delivers the chemotherapy exatecan.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06657222' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tubulis.com/our-pipeline/' target='_blank'>Tubulis: TUB-030 Drug Information Page</a> </li></ul>
NEAREST SITE: 1471 miles
NEXT Dallas
Irving,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06167317
GS-0201 Alone or With ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GS-0201, by mouth</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GS-0201 is an experimental anti-cancer therapy.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06167317' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 1481 miles
UT Health San Antonio - MD Anderson Cancer Center
San Antonio,TX
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT06774963
LNCB74 Antibody Drug Conjugate for Advanced Breast Cancer
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors (LNCB74-01) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LNCB74, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LNCB74 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in LNCB74 targets B7-H4 proteins. It delivers the chemotherapy MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06774963' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nextcure.com/pipeline/' target='_blank'>NextCure: LNCB74 Drug Information Page</a> </li></ul>
NEAREST SITE: 1481 miles
NEXT Oncology
San Antonio,TX
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT06440005
AGX101 ADC for Advanced Triple Negative Breast Cancer
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors Including Triple-Negative Breast Cancer and Pancreatic Adenocarcinoma Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AGX101, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AGX101 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in AGX101 targets TM4SF1 and delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06440005' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://angiex.com/pipeline' target='_blank'>Angiex: AGX101 Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 1481 miles
South Texas Accelerated Research Therapeutics (START)
San Antonio,TX
VISITS: 1 visit every 2 weeks
PHASE: I
NCT ID: NCT06238479
LY4101174 ADC for Advanced Triple Negative Breast Cancer
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4101174, by IV, every 2 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY4101174 is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in LY4101174 targets Nectin-4 proteins. It delivers a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06238479' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://trials.lilly.com/en-US/trial/456635' target='_blank'>Eli Lilly and Company: Trial Information Page</a> </li></ul>
NEAREST SITE: 1499 miles
The University of Kansas Cancer Center - Overland Park
Overland Park,KS
VISITS: 1 visit every week, 2 weeks on, 1 week off
PHASE: I
NCT ID: NCT05143229
Alpelisib With Sacituzumab Govitecan for Advanced HER2- Breast Cancer
Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, every week, 2 weeks on, 1 week off</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Alpelisib (Piqray®) blocks the PI3K pathway that allows cancer cells to grow.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) and sacituzumab govitecan (Trodelvy®) are approved for some types of breast cancer, but their uses in this trial are considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05143229' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/piqray' target='_blank'>Breastcancer.org: Alpelisib (Piqray®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/trodelvy' target='_blank'>Breastcancer.org: Sacituzumab Govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 1584 miles
University of Minnesota Masonic Cancer Center
Minneapolis,MN
VISITS: 1 visit every 2-3 weeks
PHASE: I
NCT ID: NCT05868226
PRE-I-SPY: Targeted Therapy and Immunotherapy for Advanced HER2+ or HER2 Low Breast Cancer
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial (PRE-I-SPY-PI) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evorpacept (ALX148) is an experimental immunotherapy called a CD47 inhibitor. Blocking CD47 may help stimulate the immune system to attack and cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a type of immunotherapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) uses the HER2-targeted <span class="highlight">antibody</span> trastuzumab to deliver the chemotherapy DM1 directly to the cancer cells.</li> <li class="seamTextUnorderedListItem">Zanidatamab is an experimental targeted therapy called a bispecific <span class="highlight">antibody</span> that binds to 2 targets on HER2.</li> <li class="seamTextUnorderedListItem">A bispecific <span class="highlight">antibody</span> binds to 2 distinct targets and may work better than traditional <span class="highlight">antibody</span> drugs.</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/FISH -.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05868226' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.quantumleaphealth.org/for-patients/i-spy-trials/' target='_blank'>Quantum Leap Healthcare Collaborative: Trial Information Page</a> </li></ul>
NEAREST SITE: 1643 miles
University of Texas MD Anderson Cancer Center
Houston,TX
VISITS: About 1 visit every 3 weeks
PHASE: I
NCT ID: NCT06475937
DM001 Antibody Drug Conjugate for Advanced Breast Cancer
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DM001, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DM001 is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> targets cancer cells, the ADC does minimal damage to normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in DM001 targets 2 proteins (bispecific): TROP2 and EGFR. It delivers the chemotherapy MMAE.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06475937' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://aacrjournals.org/cancerres/article/83/8_Supplement/LB215/725224/Abstract-LB215-A-first-in-class-anti-TROP2-EGFR' target='_blank'>AACR Abstract: DM001 for Advanced Cancers</a> </li></ul>
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT05633979
Valemetostat Targeted Therapy for Advanced HER2 Low, HER2 Ultra Low, or HER2 Null Breast Cancer
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Valemetostat, by mouth</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Valemetostat, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Valemetostat is an experimental targeted therapy called a EZH1/2 inhibitor. Blocking EZH1 and EZH2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) uses the HER2 targeted <span class="highlight">antibody</span> trastuzumab to deliver the chemotherapy DM1/deruxtecan directly to the cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 2+/ISH- or IHC 1+/ISH- or undefined.</li> <li class="seamTextUnorderedListItem">HER2 ultra low is defined as IHC 0 with faint ISH staining.</li> <li class="seamTextUnorderedListItem">HER2 null is defined as IHC 0 with no ISH staining.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05633979' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2022-0315.html' target='_blank'>MD Anderson Cancer Center: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.daiichisankyo.com/rd/pipeline/' target='_blank'>Daiichi-Sankyo: Valemetostat Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab Deruxtecan (Enhertu®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/her2-status/' target='_blank'>Metastatic Trial Talk: Why Knowing Your HER2 Status is Important</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/special-topics/enhertu-her2-low/' target='_blank'>Metastatic Trial Talk: FDA Approves Enhertu® for HER2-Low MBC</a> </li></ul>
NEAREST SITE: 1857 miles
University of Chicago Medical Center
Chicago,IL
VISITS: 2 visits every 3 weeks
PHASE: II
NCT ID: NCT04468061
Sacituzumab Govitecan with or without Pembrolizumab for Advanced Triple Negative or ER Low, HER2- Breast Cancer
Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab Govitecan (Trodelvy), by IV, every week (2 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab Govitecan (Trodelvy), by IV, every week (2 weeks on, 1 week off), ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is an antibody-drug <span class="highlight">conjugate</span> (ADC). This means it uses an <span class="highlight">antibody</span> that targets cancer cells to deliver a chemotherapy directly to these cells. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in this <span class="highlight">drug</span> targets TROP2 proteins. </li> <li class="seamTextUnorderedListItem">It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is approved for use in people with <span class="highlight">metastatic</span> triple negative breast cancer who have already received at least two other therapies for <span class="highlight">metastatic</span> disease. But its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Pembrolizumab is a type of immunotherapy called a PD-1 inhibitor. It is approved to treat certain types of cancers but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER Low. This trial is enrolling people with triple negative as well as ER Low, HER2 negative breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04468061' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-sacituzumab-govitecan-triple-negative-breast-cancer' target='_blank'>NCI Cancer Currents Blog: Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.trodelvy.com/dosing' target='_blank'>Immunomedics Drug Information Page: Trodelvy (Sacituzumab Govitecan)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/pembrolizumab' target='_blank'>Cancer Research UK: Pembrolizumab (Keytruda)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/' target='_blank'>NIH MedlinePlus: PDL1 (Immunotherapy) Tests</a> </li></ul>
NEAREST SITE: 1958 miles
Vanderbilt University/Ingram Cancer Center
Nashville,TN
VISITS: Coincides with routine care
PHASE: II
NCT ID: NCT05770531
ctDNA Tests to Support Treatment Decisions for People with Metastatic Triple Negative, PD-L1 Negative Breast Cancer
A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li> <li class="seamTextUnorderedListItem">Blood samples for ctDNA tests</li> <li class="seamTextUnorderedListItem">CT scan or MRI scan, 2 times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care chemotherapy</li> <li class="seamTextUnorderedListItem">Blood samples for ctDNA tests</li> <li class="seamTextUnorderedListItem">CT scan or MRI scan, 2 times</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Switch to sacituzumab govitecan (Trodelvy®), by IV (depending on blood test results)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream.</li> <li class="seamTextUnorderedListItem">Studying ctDNA may help your doctor decide to change your treatment earlier (if needed) and may improve your health outcomes.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05770531' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/trodelvy' target='_blank'>Breastcancer.org: Sacituzumab Govitecan (Trodelvy®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/ctdna-mbc/' target='_blank'>Metastatic Trial Talk: The Latest Research on ctDNA and MBC</a> </li></ul>
NEAREST SITE: 1959 miles
SCRI Oncology Partners
Nashville,TN
VISITS: 1 visit every 1-2 weeks
PHASE: II
NCT ID: NCT06100874
Sacituzumab Govitecan ADC and Trastuzumab Targeted Therapy for Advanced HER2+ Breast Cancer
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd), weekly, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV or injection, every 3 weeks</li> <li class="seamTextUnorderedListItem">CT or MRI scans, every 2-3 months</li> <li class="seamTextUnorderedListItem">Heart scan, every 3-4 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Herceptin® Hylecta is a form of trastuzumab that is given by injection instead of by IV.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06100874' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 2223 miles
Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
Greenville,SC
VISITS: 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT06686394
Patritumab Deruxtecan Antibody Drug Conjugate with Anti-HER2 Targeted Therapy for Advanced HER2+ Breast Cancer
HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups based on your treatment history: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Recieved T-DXd and 2-5 Lines of Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Received up to 5 Lines of Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Received T-DXd and up to 3 Lines of Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan is an experimental HER3-targeted antibody-drug <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells. </li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Patritumab deruxtecan's <span class="highlight">antibody</span> targets HER3 and delivers an anti-cancer drug.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are anti-HER2 targeted therapies commonly used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps HER2+ cancer cells grow.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06686394' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.merck.com/research/product-pipeline/' target='_blank'>Merck: Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update on Antibody-Drug Conjugates (ADCs) for MBC</a> </li></ul>
NEAREST SITE: 2314 miles
Wake Forest Baptist Health Sciences
Winston-Salem,NC
VISITS: 3 visits in 3 months
PHASE: NA
NCT ID: NCT05030038
Impact of Aromatase Inhibitors on Gut Bacteria in People with Stage 0-IV Breast Cancer
Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests, 3 times within 3 months</li> <li class="seamTextUnorderedListItem">Stool samples, 3 times within 3 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome consists of the many bacteria, viruses, and fungi found in your digestive tract. Most of the microbiome consists of bacteria in your digestive system.</li> <li class="seamTextUnorderedListItem">These bacteria can be beneficial or harmful. The harmful bacteria cause disease, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy commonly used to treat hormone receptor-positive breast cancer. The approved aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">You will collect fecal samples at home and either mail in the sample or drop it off at the lab.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05030038' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hsph.harvard.edu/nutritionsource/microbiome/' target='_blank'>Harvard University: What is the Microbiome?</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/about-us/news-personal-stories/can-gut-bacteria-help-treat-breast-cancer' target='_blank'>Breast Cancer Now: Gut Bacteria and Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromatase-inhibitors' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li></ul>
NEAREST SITE: 2385 miles
Duke University Medical Center
Durham,NC
VISITS: At least 1 visit every 1-2 months
PHASE: II
NCT ID: NCT06176261
Datopotamab Deruxtecan ADC for HER2- Breast Cancer That Spread to the Brain or Leptomeninges
DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV, daily</li> <li class="seamTextUnorderedListItem">CT or MRI scans, every 1-2 months</li> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF (optional), 1 time</li> <li class="seamTextUnorderedListItem">Heart scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd) is an experimental <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan's <span class="highlight">antibody</span> targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06176261' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/october-10-2022-supplement-breast-cancer-almanac/datopotamab-deruxtecan-shows-activity-in-advanced-triple-negative-breast-cancer/' target='_blank'>ASCO: Dato-DXd</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastastic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 2395 miles
Moffitt Cancer Center
Tampa,FL
VISITS: At least 1 visit every 1-2 weeks
PHASE: I-II
NCT ID: NCT06238921
ADC, Targeted Therapy, and Stereotactic Radiation for Metastatic Triple Negative Breast Cancer with Brain Metastases
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation</li> </ul> <p class="seamTextPara"> followed 1 week later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, weekly, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Zimberelimab, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Imaging scans, every 2 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">Zimberelimab is an experimental targeted therapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06238921' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zimberelimab' target='_blank'>National Cancer Institute: Zimberelimab</a> </li></ul>
NEAREST SITE: 2395 miles
Moffitt Cancer Center
Tampa,FL
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT06409390
Studying a New Order of Giving Currently Approved Drugs for Women with HR+, HER2- Breast Cancer
A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®)</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®)</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) or trastuzumab deruxtecan (Enhertu®)</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®)</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®)</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®) or abemaciclib (Verzenio®)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers are continually developing new drugs to treat <span class="highlight">metastatic</span> breast cancer (MBC) and understanding how to best use drugs already approved for MBC.</li> <li class="seamTextUnorderedListItem">An important question in treatment planning is the order in which drugs are given, called “drug sequencing”.</li> <li class="seamTextUnorderedListItem">All drugs in this trial are approved for <span class="highlight">metastatic</span> breast cancer.</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®), docetaxel (Taxotere®), and capecitabine (Xeloda®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) and trastuzumab deruxtecan (Enhertu®) are types of targeted therapy called <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugates</span> (ADC).</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li> <li class="seamTextUnorderedListItem">Ribociclib (Kisqali®) and abemaciclib (Verzenio®) are types of targeted therapy called CDK4/6 inhibitors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06409390' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/drug-sequencing/?utm_medium=email&utm_source=subscribers&utm_campaign=Mar2024&utm_content=Email032024' target='_blank'>Metastatic Trial Talk: What is “Drug Sequencing”?</a> </li></ul>
NEAREST SITE: 2398 miles
USF College of Medicine
Tampa,FL
VISITS: 1 visit every 3 weeks
PHASE: III
NCT ID: NCT05950945
Trastuzumab Deruxtecan ADC for People with Advanced HER2 Negative or HER2 Low Breast Cancer
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®) is a type of immunotherapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) uses the HER2-targeted <span class="highlight">antibody</span> trastuzumab to deliver the chemotherapy DM1 directly to the cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05950945' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.destinyclinicaltrials.com/en#DESTINY-breast' target='_blank'>AstraZeneca: DESTINY Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab Deruxtecan (Enhertu®)</a> </li></ul>
NEAREST SITE: 2434 miles
Georgetown University Medical Center
Washington,DC
VISITS: 1 visit every 3 weeks
PHASE: II
NCT ID: NCT06533826
Sequence of Two ADCs for Advanced HER2 Low Breast Cancer
A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients with Metastatic HER2-low Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy (TRADE DXd) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> followed by (after progression): </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">CT scans, every 2 months</li> <li class="seamTextUnorderedListItem">MRI scans, every 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> followed by (after progression): </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">CT scans, every 2 months</li> <li class="seamTextUnorderedListItem">MRI scans, every 2 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®) and datopotamab deruxtecan (Dato-DXd) are <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugates</span> (ADCs).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd)'s <span class="highlight">antibody</span> targets TROP2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">The US FDA has not approved datopotamab deruxtecan as a treatment for HER2-low <span class="highlight">metastatic</span> breast cancer.</li> <li class="seamTextUnorderedListItem">The US FDA has approved trastuzumab deruxtecan (Enhertu®) for previously treated HER2-low <span class="highlight">metastatic</span> breast cancer, and for other uses.</li> <li class="seamTextUnorderedListItem">If you are randomized to a group and have already received the first drug, you may immediately skip to the second drug.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06533826' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>
NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge,NJ
VISITS: 1 visit every 1-2 weeks
PHASE: II
NCT ID: NCT05570253
Evexomostat and Chemotherapy for People with Advanced Triple Negative Breast Cancer and High Blood Sugar or High BMI
Phase 2 Randomized Control Trial of Evexomostat (SDX-7320) in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), by IV, weekly, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320), by injection, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), by IV, weekly, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Placebo for evexomostat (SDX-7320)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320) is an experimental polymer <span class="highlight">drug</span> <span class="highlight">conjugate</span> (PDC), which is similar to an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">Evexomostat (SDX-7320) releases fumagillol, a type of targeted therapy called a MetAP2 inhibitor. Blocking MetAP2 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05570253' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aretha1.com/' target='_blank'>SynDevRx: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://syndevrx.com/lead-compound-sdx-7320/' target='_blank'>SynDevRx Drug Information Page: Evexomostat (SDX-7320)</a> </li><li class='seamTextUnorderedListItem'><a href='https://syndevrx.com/science/polymer-drug-conjugation/' target='_blank'>SynDevRx: Polymer Drug Conjugates</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/halaven' target='_blank'>Breastcancer.org: Eribulin (Halaven®)</a> </li></ul>
NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York,NY
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT06058988
Trastuzumab Deruxtecan Antibody Drug Conjugate for Metastatic HER2 Positive, Low, or Mutated Breast Cancer with Brain Metastases
Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is an antibody-drug <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC1+ or 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06058988' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab Deruxtecan (T-DXd, Enhertu®)</a> </li></ul>
NEAREST SITE: 2584 miles
Northwell Health
New York,NY
VISITS: 1 visit every 3 weeks
PHASE: II
NCT ID: NCT06172127
PHESGO Targeted Therapy After Enhertu ADC for People with Advanced HER2+ Breast Cancer
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtecan as Induction Treatment for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV, every 3 weeks for 4.5 months</li> </ul> <p class="seamTextPara"> followed 4.5 months later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PHESGO®, by injection, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®) is an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADCs).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li> <li class="seamTextUnorderedListItem">PHESGO® is a combination of two anti-HER2 targeted therapies: pertuzumab (Perjeta®) and trastuzumab (Herceptin®). It also includes a protein called hyaluronidase which helps your body absorb the targeted therapies.</li> <li class="seamTextUnorderedListItem">Pertuzumab and trastuzumab are typically given by IV. With PHESGO®, you can receive these therapies by injection.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06172127' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 2587 miles
Miami Cancer Institute at Baptist Health, Inc.
Miami,FL
VISITS: 1 visit every 1-2 weeks
PHASE: II
NCT ID: NCT06263543
Sacituzumab Govitecan ADC After T-DXd ADC for Advanced HR+, HER2 Low Breast Cancer
SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW MetaStatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (SG, Trodelvy®), by IV, weekly, 2 weeks on, 1 week off</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Although Sacituzumab govitecan (SG, Trodelvy®) is approved to treat <span class="highlight">metastatic</span> HR+/HER2 negative breast cancer, the aim of this study is to determine if it is still effective specifically in people who have already received T-DXd.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (SG, Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (SG, Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 2+/ISH- or IHC 1+/ISH- or ISH untested.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06263543' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/trodelvy' target='_blank'>Breastcancer.org: Sacituzumab Govitecan (SG, Trodelvy®)</a> </li></ul>
NEAREST SITE: 2614 miles
Yale University
New Haven,CT
VISITS: 1 visit every 3 weeks
PHASE: II
NCT ID: NCT06750484
Trastuzumab Deruxtecan Antibody Drug Conjugate for Advanced HER2 Negative Breast Cancer
Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">About half of breast cancers that are considered HER2 negative actually have low expression of HER2 (HER2 low) and may respond to anti-HER2 targeted therapies.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan is effective and increases survival in people with HER2 low breast cancers.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®)'s <span class="highlight">antibody</span> targets HER2 and delivers an anti-cancer <span class="highlight">drug</span> called deruxtecan.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06750484' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 2693 miles
Massachusetts General Hospital Cancer Center
Boston,MA
VISITS: Weekly visits for 2 out of every 3 weeks
PHASE: I-II
NCT ID: NCT04039230
Sacituzumab Govitecan and Talazoparib for Women With Metastatic Triple Negative Breast Cancer
Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy), by IV, once a week, for 2 out of every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The PARP inhibitor being used in this study is talazoparib (Talzenna®). It is approved for use in individuals with advanced triple-negative breast cancer and an inherited BRCA1 or BRCA2 mutation. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is an antibody-drug <span class="highlight">conjugate</span> (ADC). This means it uses an <span class="highlight">antibody</span> that targets cancer cells to deliver a chemotherapy directly to these cells. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in this <span class="highlight">drug</span> targets TROP2 proteins. </li> <li class="seamTextUnorderedListItem">It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy) is approved to treat some <span class="highlight">metastatic</span> triple-negative breast cancer, but its use in this trial is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04039230' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sacituzumab-govitecan' target='_blank'>NCI Drug Dictionary: Sacituzumab Govitecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ascopost.com/news/april-2020/fda-approves-sacituzumab-govitecan-hziy-for-patients-with-previously-treated-metastatic-triple-negative-breast-cancer/' target='_blank'>ASCO: FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.immunomedics.com/sacituzumab-govitecan-immu-132/' target='_blank'>Immunomedics Drug Information Page: Trodelvy (Sacituzumab Govitecan)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com/?source=google&HBX_PK=s_talazoparib&skwid=43700039109819878' target='_blank'>Pfizer Oncology: Talzenna™</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>Metastatic Trial Talk: ADCs in Breast Cancer</a> </li></ul>
NEAREST SITE: 2693 miles
Brigham and Women's Hospital
Boston,MA
VISITS: 1 visit every 2 weeks
PHASE: I
NCT ID: NCT06488378
Axatilimab Immunotherapy with Targeted Therapy for Advanced HER2 Negative Breast Cancer with BRCA1/2 or PALB2 Mutations
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axatilimab, by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, daily</li> <li class="seamTextUnorderedListItem">MRI and/or CT scans, every 2 months</li> <li class="seamTextUnorderedListItem">Electrocardiograms</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Axatilimab is an experimental immunotherapy <span class="highlight">drug</span> that may help the immune system go after and kill cancer drugs.</li> <li class="seamTextUnorderedListItem">Axatilimab is approved to treat Graft-Versus-Host Disease (GVHD), and its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">An electrocardiogram (ECG) test records electrical signals in your heart.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06488378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/clinical-trials/24-155' target='_blank'>Dana-Farber Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axatilimab' target='_blank'>National Cancer Institute: Axatilimab</a> </li></ul>
NEAREST SITE: 2693 miles
Dana-Farber Cancer Institute
Boston,MA
VISITS: 1 visit every 1-3 weeks for 1.5 years
PHASE: II
NCT ID: NCT06439693
Multiple Anti-HER2 Targeted Therapies for de Novo Metastatic HER2+ Breast Cancer
A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks for 3 months</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks for 3 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), docetaxel (Taxotere®), or nab-paclitaxel (Abraxane®), by IV, every 1-3 weeks for 3 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd), by IV, every 3 weeks for 4-5 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (Kadcyla®, T-DM1), by IV, every 3 weeks for 3 months</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by IV, every 3 weeks for 3 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily for 1 year</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks for 1 year</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks for 1 year</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The U.S. Food and <span class="highlight">Drug</span> Administration (FDA) has approved all the study drugs as a treatment option for <span class="highlight">metastatic</span> HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">In standard of care treatment, you typically change treatment after your cancer progresses.</li> <li class="seamTextUnorderedListItem">In this study, you will receive a series of treatments in a row without waiting for disease progression.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are anti-HER2 targeted therapies used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), docetaxel (Taxotere®), or nab-paclitaxel (Abraxane®) are chemotherapy drugs.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®, T-DXd) and trastuzumab emtansine (Kadcyla®, T-DM1) are <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugates</span> (ADCs).</li> <li class="seamTextUnorderedListItem">An ADC is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme that helps cancer cells grow.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06439693' target='_blank'>ClinicalTrials.gov</a> </li></ul>
NEAREST SITE: 2693 miles
Dana-Farber Cancer Institute
Boston,MA
VISITS: At least 1 visit every 1-2 weeks
PHASE: I-II
NCT ID: NCT06351332
Azenosertib Targeted Therapy with Chemotherapy and Immunotherapy for Advanced Triple Negative Breast Cancer
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azenosertib (ZN-C3), by mouth, daily, 5 days on, 2 days off</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, weekly, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">CT or MRI scans, 4 times in 7 months, then every 3 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azenosertib (ZN-C3) is an experimental targeted therapy called a WEE1 inhibitor. Blocking WEE1 may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">WEE1 is an important protein in tumor growth.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells. It is currently approved only for PD-L1 positive cancer.</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) is a chemotherapy <span class="highlight">drug</span> commonly used to treat breast cancer. it is considered standard of care for breast cancer.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06351332' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zentalis.com/pipeline/pipeline' target='_blank'>Zentalis Pharmaceuticals: Azenosertib Drug Information Page</a> </li></ul>
NEAREST SITE: 2694 miles
Massachusetts General Hospital Cancer Center
Boston,MA
VISITS: At least 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT06827613
Invikafusp Alfa Immunotherapy with ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer
A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Invikafusp alfa (STAR0602), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Invikafusp alfa (STAR0602) is an experimental bispecific <span class="highlight">antibody</span> that may target immune cells to stimulate anti-cancer activity.</li> <li class="seamTextUnorderedListItem">A bispecific <span class="highlight">antibody</span> binds to two distinct targets and may work better than traditional <span class="highlight">antibody</span> drugs.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an <span class="highlight">antibody</span> <span class="highlight">drug</span> <span class="highlight">conjugate</span> (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug <span class="highlight">conjugate</span> (ADC) is a type of therapy that combines an <span class="highlight">antibody</span> that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the <span class="highlight">antibody</span> only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">antibody</span> in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06827613' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/bispecific-antibodies-for-mbc/' target='_blank'>Metastatic Trial Talk: Bispecific Antibodies: An Emerging Class Of MBC Drugs</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>